Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » NovoSeven RT 50KIU


To avoid
As a precautionary measure

Contraindicated
NovoSeven RT 50KIU :
Type Medicine Authorised
Originator Biotech (NovoSeven RT 50KIU)
Agent Mersaco
Distributor Mersaco
Laboratory Novo Nordisk
Responsible Party Novo Nordisk AS
Origin Denmark
Manufacturer Novo Nordisk AS
Origin Denmark
ATC B02BD08

Your comment will appear shortly after approval

NovoSeven RT 50KIU :

Revision Date : 18/12/2013


Effect Frequency
ALT increased Rare
Anaphylactic reactions Not known
Angina pectoris Rare
Angioedema (Angioneurotic oedema) (Quincke oedema) Not known
Antithrombin III decreased Rare
Blood alkaline phosphatase increased Rare
Blood lactate dehydrogenase increased Rare
Cardiac arrest Not known
Cerebral artery occlusion Rare
Cerebral infarction Rare
Cerebral ischaemia Rare
Cerebrovascular accident Rare
Coagulopathy Rare
Deep vein thrombosis Uncommon
Dermatitis allergic Uncommon
Disseminated intravascular coagulation Rare
Drug ineffective Not known
Fibrin D dimer increased Rare
Fibrin degradation products increased Rare
Flushing Not known
Headache Rare
Hypersensitivity Rare
Inhibiting antibodies Not known
Injection site pain Rare
Injection site reaction Rare
Intestinal ischaemia Rare
Intracardiac thrombus Not known
Myocardial infarction Rare
Nausea Rare
Peripheral artery thrombosis Rare
Peripheral ischaemia Rare
Portal vein thrombosis Uncommon
Prothrombin level increased Rare
Pruritus Uncommon
Pulmonary embolism Uncommon
Pyrexia Uncommon
Rash erythematous Uncommon
Renal artery thrombosis Rare
Renal vein thrombosis Uncommon
Skin rash Uncommon
Therapeutic response decreased Uncommon
Thromboembolic event Uncommon
Thromboembolism arterial Rare
Thromboembolism venous Uncommon
Thrombophlebitis Uncommon
Thrombophlebitis superficial Uncommon
Urticaria Uncommon
Vessel puncture site thrombosis Uncommon

Different Units By MoH Code

Revision Date : 11/01/2013

NovoSeven RT 50KIU  MoH 5540 :
Form Powder and solvent for solution for injection
Packaging Pre-filled Syringes + Vials (Type I glass)
Package Size 1+1
Strength 1mg (50KIU)
Public Price 1145093 L.L.
Stratum E1
NSSF ✔
Quarantine ✔
Reg. Number 218019/09
Submission date 01/01/2009
Registration Year 2009


Price Comparison

● Country: Italy
● Package Size: 1+1x1.1ml
● Public Price: 1079.12 EUR ( 19,834,279.56 LBP )
● Pack size unit used: 1
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Exfactory Price: 653.85 EUR
● Pricing Date: 17/12/2019
● Type: Medicine Authorised

● Country: Germany
● Package Size: 1
● Public Price: 927.81 EUR ( 17,053,194.19 LBP )
● Pack size unit used: 1
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Pricing Date: 24/10/2020
● Type: Medicine Authorised

● Country: Qatar
● Package Size: 1 powder vial + 1 Solvent pre-filled syringe + vial adapter
● Public Price: 3963 QAR ( 16,448,669.28 LBP )
● Pack size unit used: 1
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Pharmacy Price: 3255.49386266 QAR ( 13512122.606602 LBP )
● Pricing Date: 28/01/2021
● Type: Medicine Authorised

● Country: Oman
● Package Size: 1+1
● Public Price: 417.29 OMR ( 16,399,705.65 LBP )
● Pack size unit used: 1
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Pricing Date: 19/02/2021
● Type: Medicine Authorised

● Country: Kuweit
● Package Size: 1+1
● Public Price: 319.2 KWD ( 15,822,769.54 LBP )
● Pack size unit used: 1
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Pharmacy Price: 269.67 KWD ( 13367563.4736 LBP )
● Pricing Date: 07/02/2021
● Type: Medicine Authorised

● Country: Switzerland
● Package Size: 1+1
● Public Price: 907.55 CHF ( 15,483,029.89 LBP )
● Pack size unit used: 1
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Exfactory Price: 845.41 CHF
● Pricing Date: 04/04/2021
● Type: Medicine Authorised

● Country: Abu Dhabi
● Package Size: 1+1x1.1ml
● Public Price: 3703 AED ( 15,222,884.88 LBP )
● Pack size unit used: 1
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Pharmacy Price: 3154.78 AED ( 12969174.3888 LBP )
● Pricing Date: 27/01/2021
● Type: Medicine Authorised

● Country: UAE
● Package Size: 1 Vial (Powder) + 1 Solvent Vial (1.1ml)
● Public Price: 3703 AED ( 15,222,884.88 LBP )
● Pack size unit used: 1
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Pharmacy Price: 3154.78 AED ( 12969174.3888 LBP )
● Pricing Date: 21/08/2019
● Type: Medicine Authorised

● Country: Finland
● Package Size: 1+1x1ml
● Public Price: 809.89 EUR ( 14,885,818.69 LBP )
● Pack size unit used: 1
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Reference: Kela
● Pricing Date: 22/04/2021
● Type: Medicine Authorised

● Country: Bahrain
● Package Size: 1+1
● Public Price: 352.25 BHD ( 14,132,541.23 LBP )
● Pack size unit used: 1
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Reference: nhra
● Pricing Date: 09/02/2021
● Type: Medicine Authorised

● Country: Denmark
● Package Size: 1+1
● Public Price: 5318.1 DKK ( 13,087,684.56 LBP )
● Pack size unit used: 1
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Pharmacy Price: 3948.91 DKK ( 9718149.0427 LBP )
● Reference: Danish Medicine Agency
● Pricing Date: 19/05/2021
● Type: Medicine Authorised

● Country: Iceland
● Package Size: 1+1
● Public Price: 110287 ISK ( 12,226,416.82 LBP )
● Pack size unit used: 1
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Pharmacy Price: 84672 ISK ( 9386737.92 LBP )
● Reference: Icelandic Medicines Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Czech Republic
● Package Size: 1+1x1ml
● Public Price: 17583.04 CZK ( 12,145,660.71 LBP )
● Pack size unit used: 1
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Reference: SUKL
● Pricing Date: 28/02/2020
● Type: Medicine Authorised

● Country: Greece
● Package Size: 1+1
● Public Price: 642.66 EUR ( 11,812,122.93 LBP )
● Pack size unit used: 1
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Reference: National Organization for Medicines
● Pricing Date: 25/03/2019
● Type: Medicine Non Marketed

● Country: Spain
● Package Size: 1 vial + 1xdisolvente
● Public Price: 639 EUR ( 11,744,851.95 LBP )
● Pack size unit used: 1
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Reference: Agencia Española de Medicamentos y Productos Sanitarios
● Pricing Date: 06/05/2021
● Type: Medicine Non Marketed

● Country: France
● Package Size: 1+1
● Public Price: 608 EUR ( 11,175,070.40 LBP )
● Pack size unit used: 1
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Reference: ansm
● Pricing Date: 15/05/2021
● Type: Medicine Authorised

● Country: KSA
● Package Size: 1mg
● Public Price: 2640 SAR ( 10,640,203.20 LBP )
● Pack size unit used: 1
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Reference: sfda
● Pricing Date: 16/01/2021
● Type: Medicine Authorised

● Country: UK
● Package Size: 1+1
● Public Price: 525.2 GBP ( 10,583,184.40 LBP )
● Pack size unit used: 1
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Reference: DMD
● Pricing Date: 08/03/2021
● Type: Medicine Authorised

● Country: Norway
● Package Size: 1
● Public Price: 6048.4 NOK ( 10,465,365.07 LBP )
● Pack size unit used: 1
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Pharmacy Price: 4715.41 NOK ( 8158932.4607 LBP )
● Reference: Norwegian Medicine Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Sweden
● Package Size: 1+1
● Public Price: 5733.56 SEK ( 10,321,038.69 LBP )
● Pack size unit used: 1
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Pharmacy Price: 5575.79 SEK ( 10037035.3369 LBP )
● Pricing Date: 23/04/2020
● Type: Medicine Authorised

● Country: Belgium
● Package Size: 1+1x1.1ml
● Public Price: 532 EUR ( 9,778,186.60 LBP )
● Pack size unit used: 1
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Reference: cbip
● Pricing Date: 02/12/2020
● Type: Medicine Authorised

● Country: Lebanon
● Form: Powder and solvent for solution for injection
● Package Size: 1+1
● Public Price: 1145093 LBP ( 1,145,093.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Pricing Date: 10/01/2024

● Country: The Netherlands
● Package Size: 1
● Reference: Zorginstituut Nederland
● Pricing Date: 15/06/2019
● Type: Medicine Non Marketed

● Country: New Zealand
● Package Size: 1 inj
● Exfactory Price: 1178.3 NZD
● Reference: New Zealand Pharmaceutical Management Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Portugal
● Package Size: 1+1
● Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
● Pricing Date: 22/04/2019

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries

Note

Acquired haemophilia : (Adults)
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Cost/Day: 6474,72 EUR ( 118,992,443.70 LBP )
● Cost/Month: 6474,72 EUR ( 118,992,443.70 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Cost/Day: 6474,72 EUR ( 118,992,443.70 LBP )
● Cost/Month: 6474,72 EUR ( 118,992,443.70 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Cost/Day: 6474,72 EUR ( 118,992,443.70 LBP )
● Cost/Month: 6474,72 EUR ( 118,992,443.70 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Cost/Day: 6474,72 EUR ( 118,992,443.70 LBP )
● Cost/Month: 6474,72 EUR ( 118,992,443.70 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1079,12 EUR ( 19,832,073.95 LBP )
● Cost/Day: 6474,72 EUR ( 118,992,443.70 LBP )
● Cost/Month: 6474,72 EUR ( 118,992,443.70 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Cost/Day: 5566,86 EUR ( 102,303,358.30 LBP )
● Cost/Month: 5566,86 EUR ( 102,303,358.30 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Cost/Day: 5566,86 EUR ( 102,303,358.30 LBP )
● Cost/Month: 5566,86 EUR ( 102,303,358.30 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Cost/Day: 5566,86 EUR ( 102,303,358.30 LBP )
● Cost/Month: 5566,86 EUR ( 102,303,358.30 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Cost/Day: 5566,86 EUR ( 102,303,358.30 LBP )
● Cost/Month: 5566,86 EUR ( 102,303,358.30 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 927,81 EUR ( 17,038,306.35 LBP )
● Cost/Day: 5566,86 EUR ( 102,303,358.30 LBP )
● Cost/Month: 5566,86 EUR ( 102,303,358.30 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Cost/Day: 23778 QAR ( 98,692,015.68 LBP )
● Cost/Month: 23778 QAR ( 98,692,015.68 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Cost/Day: 23778 QAR ( 98,692,015.68 LBP )
● Cost/Month: 23778 QAR ( 98,692,015.68 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Cost/Day: 23778 QAR ( 98,692,015.68 LBP )
● Cost/Month: 23778 QAR ( 98,692,015.68 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Cost/Day: 23778 QAR ( 98,692,015.68 LBP )
● Cost/Month: 23778 QAR ( 98,692,015.68 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3963 QAR ( 16,448,669.28 LBP )
● Cost/Day: 23778 QAR ( 98,692,015.68 LBP )
● Cost/Month: 23778 QAR ( 98,692,015.68 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Cost/Day: 2503,74 OMR ( 98,369,151.50 LBP )
● Cost/Month: 2503,74 OMR ( 98,369,151.50 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Cost/Day: 2503,74 OMR ( 98,369,151.50 LBP )
● Cost/Month: 2503,74 OMR ( 98,369,151.50 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Cost/Day: 2503,74 OMR ( 98,369,151.50 LBP )
● Cost/Month: 2503,74 OMR ( 98,369,151.50 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Cost/Day: 2503,74 OMR ( 98,369,151.50 LBP )
● Cost/Month: 2503,74 OMR ( 98,369,151.50 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 417,29 OMR ( 16,388,308.50 LBP )
● Cost/Day: 2503,74 OMR ( 98,369,151.50 LBP )
● Cost/Month: 2503,74 OMR ( 98,369,151.50 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Cost/Day: 1915,2 KWD ( 94,926,703.20 LBP )
● Cost/Month: 1915,2 KWD ( 94,926,703.20 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Cost/Day: 1915,2 KWD ( 94,926,703.20 LBP )
● Cost/Month: 1915,2 KWD ( 94,926,703.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Cost/Day: 1915,2 KWD ( 94,926,703.20 LBP )
● Cost/Month: 1915,2 KWD ( 94,926,703.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Cost/Day: 1915,2 KWD ( 94,926,703.20 LBP )
● Cost/Month: 1915,2 KWD ( 94,926,703.20 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 319,2 KWD ( 15,812,855.52 LBP )
● Cost/Day: 1915,2 KWD ( 94,926,703.20 LBP )
● Cost/Month: 1915,2 KWD ( 94,926,703.20 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Cost/Day: 5445,3 CHF ( 92,893,061.25 LBP )
● Cost/Month: 5445,3 CHF ( 92,893,061.25 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Cost/Day: 5445,3 CHF ( 92,893,061.25 LBP )
● Cost/Month: 5445,3 CHF ( 92,893,061.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Cost/Day: 5445,3 CHF ( 92,893,061.25 LBP )
● Cost/Month: 5445,3 CHF ( 92,893,061.25 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Cost/Day: 5445,3 CHF ( 92,893,061.25 LBP )
● Cost/Month: 5445,3 CHF ( 92,893,061.25 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 907,55 CHF ( 15,473,646.75 LBP )
● Cost/Day: 5445,3 CHF ( 92,893,061.25 LBP )
● Cost/Month: 5445,3 CHF ( 92,893,061.25 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 3703 AED ( 15,222,884.88 LBP )
● Cost/Day: 22218 AED ( 91,337,309.28 LBP )
● Cost/Month: 22218 AED ( 91,337,309.28 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Cost/Day: 4859,34 EUR ( 89,308,662.95 LBP )
● Cost/Month: 4859,34 EUR ( 89,308,662.95 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Cost/Day: 4859,34 EUR ( 89,308,662.95 LBP )
● Cost/Month: 4859,34 EUR ( 89,308,662.95 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Cost/Day: 4859,34 EUR ( 89,308,662.95 LBP )
● Cost/Month: 4859,34 EUR ( 89,308,662.95 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Cost/Day: 4859,34 EUR ( 89,308,662.95 LBP )
● Cost/Month: 4859,34 EUR ( 89,308,662.95 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 809,89 EUR ( 14,869,460.45 LBP )
● Cost/Day: 4859,34 EUR ( 89,308,662.95 LBP )
● Cost/Month: 4859,34 EUR ( 89,308,662.95 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Cost/Day: 2113,5 BHD ( 84,775,187.01 LBP )
● Cost/Month: 2113,5 BHD ( 84,775,187.01 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Cost/Day: 2113,5 BHD ( 84,775,187.01 LBP )
● Cost/Month: 2113,5 BHD ( 84,775,187.01 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Cost/Day: 2113,5 BHD ( 84,775,187.01 LBP )
● Cost/Month: 2113,5 BHD ( 84,775,187.01 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Cost/Day: 2113,5 BHD ( 84,775,187.01 LBP )
● Cost/Month: 2113,5 BHD ( 84,775,187.01 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 352,25 BHD ( 14,122,511.04 LBP )
● Cost/Day: 2113,5 BHD ( 84,775,187.01 LBP )
● Cost/Month: 2113,5 BHD ( 84,775,187.01 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Cost/Day: 31908,6 DKK ( 78,524,630.76 LBP )
● Cost/Month: 31908,6 DKK ( 78,524,630.76 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Cost/Day: 31908,6 DKK ( 78,524,630.76 LBP )
● Cost/Month: 31908,6 DKK ( 78,524,630.76 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Cost/Day: 31908,6 DKK ( 78,524,630.76 LBP )
● Cost/Month: 31908,6 DKK ( 78,524,630.76 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Cost/Day: 31908,6 DKK ( 78,524,630.76 LBP )
● Cost/Month: 31908,6 DKK ( 78,524,630.76 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 5318,1 DKK ( 13,087,438.46 LBP )
● Cost/Day: 31908,6 DKK ( 78,524,630.76 LBP )
● Cost/Month: 31908,6 DKK ( 78,524,630.76 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Cost/Day: 661722 ISK ( 73,358,500.92 LBP )
● Cost/Month: 661722 ISK ( 73,358,500.92 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Cost/Day: 661722 ISK ( 73,358,500.92 LBP )
● Cost/Month: 661722 ISK ( 73,358,500.92 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Cost/Day: 661722 ISK ( 73,358,500.92 LBP )
● Cost/Month: 661722 ISK ( 73,358,500.92 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Cost/Day: 661722 ISK ( 73,358,500.92 LBP )
● Cost/Month: 661722 ISK ( 73,358,500.92 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 110287 ISK ( 12,226,416.82 LBP )
● Cost/Day: 661722 ISK ( 73,358,500.92 LBP )
● Cost/Month: 661722 ISK ( 73,358,500.92 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Cost/Day: 105498,24 CZK ( 72,873,798.48 LBP )
● Cost/Month: 105498,24 CZK ( 72,873,798.48 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Cost/Day: 105498,24 CZK ( 72,873,798.48 LBP )
● Cost/Month: 105498,24 CZK ( 72,873,798.48 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Cost/Day: 105498,24 CZK ( 72,873,798.48 LBP )
● Cost/Month: 105498,24 CZK ( 72,873,798.48 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Cost/Day: 105498,24 CZK ( 72,873,798.48 LBP )
● Cost/Month: 105498,24 CZK ( 72,873,798.48 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 17583,04 CZK ( 12,145,633.08 LBP )
● Cost/Day: 105498,24 CZK ( 72,873,798.48 LBP )
● Cost/Month: 105498,24 CZK ( 72,873,798.48 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Cost/Day: 3855,96 EUR ( 70,855,092.75 LBP )
● Cost/Month: 3855,96 EUR ( 70,855,092.75 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Cost/Day: 3855,96 EUR ( 70,855,092.75 LBP )
● Cost/Month: 3855,96 EUR ( 70,855,092.75 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Cost/Day: 3855,96 EUR ( 70,855,092.75 LBP )
● Cost/Month: 3855,96 EUR ( 70,855,092.75 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Cost/Day: 3855,96 EUR ( 70,855,092.75 LBP )
● Cost/Month: 3855,96 EUR ( 70,855,092.75 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 642,66 EUR ( 11,799,992.10 LBP )
● Cost/Day: 3855,96 EUR ( 70,855,092.75 LBP )
● Cost/Month: 3855,96 EUR ( 70,855,092.75 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Cost/Day: 3834 EUR ( 70,469,111.70 LBP )
● Cost/Month: 3834 EUR ( 70,469,111.70 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Cost/Day: 3834 EUR ( 70,469,111.70 LBP )
● Cost/Month: 3834 EUR ( 70,469,111.70 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Cost/Day: 3834 EUR ( 70,469,111.70 LBP )
● Cost/Month: 3834 EUR ( 70,469,111.70 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Cost/Day: 3834 EUR ( 70,469,111.70 LBP )
● Cost/Month: 3834 EUR ( 70,469,111.70 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 639 EUR ( 11,744,851.95 LBP )
● Cost/Day: 3834 EUR ( 70,469,111.70 LBP )
● Cost/Month: 3834 EUR ( 70,469,111.70 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Cost/Day: 3648 EUR ( 67,050,422.40 LBP )
● Cost/Month: 3648 EUR ( 67,050,422.40 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Cost/Day: 3648 EUR ( 67,050,422.40 LBP )
● Cost/Month: 3648 EUR ( 67,050,422.40 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Cost/Day: 3648 EUR ( 67,050,422.40 LBP )
● Cost/Month: 3648 EUR ( 67,050,422.40 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Cost/Day: 3648 EUR ( 67,050,422.40 LBP )
● Cost/Month: 3648 EUR ( 67,050,422.40 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 608 EUR ( 11,175,070.40 LBP )
● Cost/Day: 3648 EUR ( 67,050,422.40 LBP )
● Cost/Month: 3648 EUR ( 67,050,422.40 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Cost/Day: 15840 SAR ( 63,841,219.20 LBP )
● Cost/Month: 15840 SAR ( 63,841,219.20 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Cost/Day: 15840 SAR ( 63,841,219.20 LBP )
● Cost/Month: 15840 SAR ( 63,841,219.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Cost/Day: 15840 SAR ( 63,841,219.20 LBP )
● Cost/Month: 15840 SAR ( 63,841,219.20 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Cost/Day: 15840 SAR ( 63,841,219.20 LBP )
● Cost/Month: 15840 SAR ( 63,841,219.20 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 2640 SAR ( 10,640,203.20 LBP )
● Cost/Day: 15840 SAR ( 63,841,219.20 LBP )
● Cost/Month: 15840 SAR ( 63,841,219.20 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Cost/Day: 3151,2 GBP ( 63,495,076.27 LBP )
● Cost/Month: 3151,2 GBP ( 63,495,076.27 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Cost/Day: 3151,2 GBP ( 63,495,076.27 LBP )
● Cost/Month: 3151,2 GBP ( 63,495,076.27 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Cost/Day: 3151,2 GBP ( 63,495,076.27 LBP )
● Cost/Month: 3151,2 GBP ( 63,495,076.27 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Cost/Day: 3151,2 GBP ( 63,495,076.27 LBP )
● Cost/Month: 3151,2 GBP ( 63,495,076.27 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 525,2 GBP ( 10,579,154.25 LBP )
● Cost/Day: 3151,2 GBP ( 63,495,076.27 LBP )
● Cost/Month: 3151,2 GBP ( 63,495,076.27 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Cost/Day: 36290,4 NOK ( 62,791,498.30 LBP )
● Cost/Month: 36290,4 NOK ( 62,791,498.30 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Cost/Day: 36290,4 NOK ( 62,791,498.30 LBP )
● Cost/Month: 36290,4 NOK ( 62,791,498.30 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Cost/Day: 36290,4 NOK ( 62,791,498.30 LBP )
● Cost/Month: 36290,4 NOK ( 62,791,498.30 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Cost/Day: 36290,4 NOK ( 62,791,498.30 LBP )
● Cost/Month: 36290,4 NOK ( 62,791,498.30 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 6048,4 NOK ( 10,464,672.96 LBP )
● Cost/Day: 36290,4 NOK ( 62,791,498.30 LBP )
● Cost/Month: 36290,4 NOK ( 62,791,498.30 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Cost/Day: 34401,36 SEK ( 61,925,584.11 LBP )
● Cost/Month: 34401,36 SEK ( 61,925,584.11 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Cost/Day: 34401,36 SEK ( 61,925,584.11 LBP )
● Cost/Month: 34401,36 SEK ( 61,925,584.11 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Cost/Day: 34401,36 SEK ( 61,925,584.11 LBP )
● Cost/Month: 34401,36 SEK ( 61,925,584.11 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Cost/Day: 34401,36 SEK ( 61,925,584.11 LBP )
● Cost/Month: 34401,36 SEK ( 61,925,584.11 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 5733,56 SEK ( 10,320,030.63 LBP )
● Cost/Day: 34401,36 SEK ( 61,925,584.11 LBP )
● Cost/Month: 34401,36 SEK ( 61,925,584.11 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Cost/Day: 3192 EUR ( 58,669,119.60 LBP )
● Cost/Month: 3192 EUR ( 58,669,119.60 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Cost/Day: 3192 EUR ( 58,669,119.60 LBP )
● Cost/Month: 3192 EUR ( 58,669,119.60 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Cost/Day: 3192 EUR ( 58,669,119.60 LBP )
● Cost/Month: 3192 EUR ( 58,669,119.60 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Cost/Day: 3192 EUR ( 58,669,119.60 LBP )
● Cost/Month: 3192 EUR ( 58,669,119.60 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 532 EUR ( 9,778,186.60 LBP )
● Cost/Day: 3192 EUR ( 58,669,119.60 LBP )
● Cost/Month: 3192 EUR ( 58,669,119.60 LBP )
Acquired haemophilia : (Adults)
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Cost/Day: 6870558 LBP ( 6,870,558.00 LBP )
● Cost/Month: 6870558 LBP ( 6,870,558.00 LBP )
Congenital FVII deficiency : (Adults)
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Cost/Day: 6870558 LBP ( 6,870,558.00 LBP )
● Cost/Month: 6870558 LBP ( 6,870,558.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors IX : (Adults)
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Cost/Day: 6870558 LBP ( 6,870,558.00 LBP )
● Cost/Month: 6870558 LBP ( 6,870,558.00 LBP )
Congenital haemophilia with inhibitors to coagulation factors VIII : (Adults)
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Cost/Day: 6870558 LBP ( 6,870,558.00 LBP )
● Cost/Month: 6870558 LBP ( 6,870,558.00 LBP )
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA : (Adults)
● Cost/Unit: 1145093 LBP ( 1,145,093.00 LBP )
● Cost/Day: 6870558 LBP ( 6,870,558.00 LBP )
● Cost/Month: 6870558 LBP ( 6,870,558.00 LBP )
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info